Johan Lindberg

Science for Life Laboratory — Sweden

Biochemistry, Genetics and Molecular Biology · Life Sciences

52h-index12.6kcitations331works4.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(81), Prostate Cancer Treatment and Research(68), Prostate Cancer Diagnosis and Treatment(29), Sarcoma Diagnosis and Treatment(24), Cancer Diagnosis and Treatment(20)

Publications330 total

Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer
New England Journal of Medicine·2025
Associations of the intestinal microbiota with plasma bile acids and inflammation markers in Crohn’s disease and ulcerative colitis
Scientific Reports·2025Open Access
Reliable on-treatment prognostication and target identification with a customized assay for circulating tumor DNA in patients with newly diagnosed pancreatic cancer
Scientific Reports·2025Open Access
Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer
New England Journal of Medicine·2025· 27 cited
Exploring novel genomic biomarkers for response and survival after neoadjuvant chemotherapy and radical cystectomy of muscle-invasive bladder cancer
ESMO Open·2025Open Access
Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer
Molecular Oncology·2025· 1 citedOpen Access
Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform Trial
European Urology Oncology·2025· 2 citedOpen Access
Deep targeted sequencing of circulating tumor DNA to inform treatment in patients with metastatic castration-resistant prostate cancer
Journal of Experimental & Clinical Cancer Research·2025· 1 citedOpen Access
Author response for "Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer"
2025
Low-dose aspirin to reduce recurrence rate in colorectal cancer patients with PI3K pathway alterations: 3-year results from a randomized placebo-controlled trial.
Journal of Clinical Oncology·2025· 14 cited
Prospective Screening of Cancer Syndromes in Patients with Mesenchymal Tumors
Cancers·2024· 2 citedOpen Access
1636P Health-related quality of life outcomes of androgen receptor pathway inhibitors versus taxanes versus standard of care in metastatic castration-resistant prostate cancer: Results from the ProBio trial
Annals of Oncology·2024
1623P Prognostic value of circulating tumour DNA fraction in metastatic castration-resistant prostate cancer: Insights from the ProBio trial
Annals of Oncology·2024Open Access
1644P PSA trajectories and prediction of time to no-longer clinically benefitting in metastatic castration-resistant prostate cancer: Insights from the ProBio trial
Annals of Oncology·2024Open Access
Author Correction: Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial
Nature Medicine·2024Open Access
Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial
Nature Medicine·2024· 18 citedOpen Access
71465 - Reflex CRC Initiative - Advancing Colorectal Cancer Care through Comprehensive Genetic Testing
British journal of surgery·2024Open Access
Supplementary Data 3 from Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma
2024Open Access
Supplementary Figure 1 from Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma
2024Open Access
Supplementary Data 4 from Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma
2024Open Access
page 1 of 17Next →

Frequent Co-authors

Henrik Grönberg(20), Lars Egevad(13), Daniel Klevebring(7), Mattias Rantalainen(6), Joakim Lundeberg(6), Fredrik Wiklund(5), Bram De Laere(5), Ina Schuppe‐Koistinen(5), Peter Wiklund(4), Ian G. Mills(4), Lars Klareskog(4), Wennuan Liu(4), Jianfeng Xu(4), Jeffrey Yachnin(4), Luc Dirix(4), Ralf J. O. Torgrip(4), Sören Lehmann(3), Jielin Sun(3), Tapio Visakorpi(3), Markus Mayrhofer(3)